Transcriptomics

Dataset Information

0

LATS1/2 Loss Promote Tumor Immune Evasion in Endometrial Cancer through Downregulating MHC-I Expression


ABSTRACT: LATS1/2 is frequently mutated and down-regulated in endometrial cancer (EC), but the contribution of LATS1/2 to endometrial tumor progression remains unclear. Here, we discovered an unexpected role of LATS1/2 in regulating MHC class I expression in EC. We demonstrate that the knockout of LATS1/2 in EC cells resulted in significant down-regulation of multiple genes of MHC/HLA Class I family and leaded to insensitivity to tumor immunotherapy. Furthermore, we found that the regulation of LATS1/2 on MHC/HLA expression does not depend on the classical Hippo pathway but on their direct interaction with STAT1 to phosphorylate STAT1 to promote STAT1 accumulating and moving into the nucleus to enhance the transcriptional activation of IRF1/NLRC5 on MHC-I. The kinase-dead mutant LATS1/2 attenuates STAT1 phosphorylation at Ser727. The expressions of LATS1/2, MHC-I, CD8A and p-STAT1(S727)are positive correlation in tissues of EC confirming our findings furtherly. Furthermore, LATS1/2 expression was negatively correlated with tumor stage in EC tissues. These findings reveal novel molecular mechanisms underlying tumor immunogenicity deficiency and elucidate the potential immunotherapy biomarker targeting LATS1/2 in EC.

ORGANISM(S): Homo sapiens

PROVIDER: GSE241847 | GEO | 2024/02/28

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-06-16 | PXD043500 | Pride
2013-02-28 | GSE40728 | GEO
2024-05-22 | PXD049188 | Pride
2013-02-28 | E-GEOD-40728 | biostudies-arrayexpress
| PRJNA1010234 | ENA
2021-10-13 | GSE183185 | GEO
2022-12-16 | PXD038303 | Pride
2022-12-16 | PXD038065 | Pride
2022-12-16 | PXD038068 | Pride
2022-12-16 | PXD038636 | Pride